Results 91 to 100 of about 206,954 (242)

Development of a Rapid and Ultrasensitive RIA Method for Estrogen (E2, E1, E1-S) Determination with Selective Solid Phase Extraction

The International Journal of Biological Markers, 1997
The inhibition of the proliferative stimulation exercised by estrogens on neoplastic cells is the goal of all endocrine therapies in breast cancer. Under various circumstances, e.g.
A. Martinetti, E. Seregni, E. Bajetta, G.F. Bolelli, L. Ferrari, S. Massaron, C. Botti, E. Bombardieri   +7 more
doaj   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

BMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang, Xueyin Hu, Wei Cheng, Lumeng Zhang, Yuanfang Chen, Qinrui Fu, Luntao Liu, Saijun Fan   +7 more
wiley   +1 more source

3D bioprinting in oral and craniomaxillofacial tissue regeneration: Progress, challenges, and future directions

BMEMat, EarlyView.
This paper summarized the application of 3D bioprinting in the regeneration of various tissues in the oral and craniomaxillofacial fields, including the required biomaterials and printing techniques. Abstract Oral and craniomaxillofacial tissues are essential for maintaining oral functions, including respiration, mastication, swallowing, and speech ...
Huilu Zhan, Haohao Ni, Xingge Yu, Mazaher Gholipourmalekabadi, Tianqi Wang, Kaili Lin, Jinsong Pan, Changyong Yuan   +7 more
wiley   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Fractal Anatomy of Human Organs: A Narrative Review of Structure, Function, and Clinical Perspectives

Clinical Anatomy, EarlyView.
ABSTRACT Fractal geometry describes complex, self‐similar patterns that repeat across spatial scales and is increasingly recognized as relevant in anatomical research. Indeed, the fractal organization is consistently observed in respiratory, cardiovascular, gastrointestinal, nervous, renal, hepatic, and dermatological systems.
Immacolata Belviso, Jacopo Junio Valerio Branca, Giulia Guarnieri, Annamaria Morelli, Alessandra Pacini, Daniele Della Posta, Domenico Ribatti, Ferdinando Paternostro   +7 more
wiley   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger, Hannah F. Todd, Jonathan M. Yarimi, Timothy E. Lotze, Nikita M. Shukla, Kristen S. Fisher, Alexander J. Sandweiss   +6 more
wiley   +1 more source

Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma

Biomarker Research
Background Uveal melanoma is the most common non-cutaneous melanoma and is an intraocular malignancy affecting nearly 7,000 individuals per year worldwide.
Ashley N. Anderson, Patrick Conley, Christopher D. Klocke, Sidharth K. Sengupta, Amara Pang, Hannah C. Farley, Abigail R. Gillingham, Aubrey D. Dawson, Yichen Fan, Jocelyn A. Jones, Summer L. Gibbs, Alison H. Skalet, Guanming Wu, Melissa H. Wong   +13 more
doaj   +1 more source

Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer

Cancers
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) presents significant diagnostic and prognostic challenges, as current biomarkers frequently fail to accurately stage disease, predict rapid metastatic recurrence (rPDAC), or assess response to neoadjuvant therapy (NAT).
Ranish K. Patel, Michael Parappilly, Hannah C. Farley, Emile J. Latour, Lei G. Wang, Ashvin M. Nair, Ethan S. Lu, Zachary Sims, Byung Park, Katherine Nelson, Skye C. Mayo, Gordon B. Mills, Brett C. Sheppard, Young Hwan Chang, Summer L. Gibbs, Adel Kardosh, Charles D. Lopez, Melissa H. Wong   +17 more
openaire   +2 more sources

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source